Think out loud, advise researchers, and name an underappreciated method of decision research.

Published Date: 14 Jun 2023

Think quickly: if you're running a race and pass the person in second place, where are you now? A lot of people will automatically say "first place.". Some people do, however, realize the truth after some thought.

Read Full News

Latest News

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 Recap: Psychiatry News & Updates Chelsie Derman

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

3 Psychiatry Headlines You Missed in June 2026 Chelsie Derman

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

First Half 2026 Recap – Psychiatry Chelsie Derman

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

What The FDA Psychedelic Hearing Means for Psychiatrists

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

News All Time

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD Jonathan Downar, MD, PhD

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Lower TMS Intensity Correlates With Greater Depression Improvement Chelsie Derman

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Safety Concerns Halt Depression Trials; Gen Z and Alcohol; Prescribing Benzos

— News and commentary from the psychiatry world

Walmart Pasta Recall; 'Ketamine Bladder' in Kids; Panettiere's Cause of Death

Health news and commentary gathered by MedPage Today staff

Meta Reaches $18B Settlement With States in Trial Over Teen Social Media Addiction

Meta agreed to adopt a series of safety features

Deaths at Psychedelic Clinics; AI Mental Health Data; School Corporal Punishment

News and commentary from the psychiatry world

Recommended News For You

Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

The Kansas Cancer Center awarded two Indian American doctors professorships.

More Evidence Ties Microplastics to Lung Cancer

QOL Maintained With Giredestrant Combo in Advanced BC

Experts say oncology, primary care coordination necessary for best cancer patient outcomes

Recommended Articles For You

Treating Methemoglobinemia: What You Need to Know Now! 

The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options  

Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence 

Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advances in "next generation" photoactive cancer therapy

2.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

3.

The American College of Physicians updated its recommendations for colorectal cancer screening.

4.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

1.

Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions

2.

Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis

3.

Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy

4.

Modern Developments in Oncology for Specialists

5.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

2.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

3.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

4.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

5.

Navigating the Complexities of Ph Negative ALL - Part XII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot